Northland Capmk Has Optimistic View of BrainsWay Q4 Earnings

BrainsWay Ltd. (NASDAQ:BWAY - Free Report) - Analysts at Northland Capmk lifted their Q4 2024 earnings estimates for shares of BrainsWay in a research report issued on Tuesday, November 12th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings of $0.02 per share for the quarter, up from their prior forecast of $0.01. The consensus estimate for BrainsWay's current full-year earnings is $0.05 per share.

BrainsWay (NASDAQ:BWAY - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.03. The company had revenue of $10.50 million for the quarter, compared to analysts' expectations of $10.07 million. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. During the same quarter in the previous year, the firm posted ($0.01) earnings per share.

Several other research analysts have also issued reports on the stock. HC Wainwright restated a "buy" rating and set a $16.00 price target on shares of BrainsWay in a report on Monday, October 21st. Northland Securities boosted their target price on shares of BrainsWay from $11.00 to $12.50 and gave the company an "outperform" rating in a report on Thursday, October 3rd.

BrainsWay Stock Performance

Shares of BWAY traded down $0.41 during mid-day trading on Friday, reaching $9.12. 41,232 shares of the company were exchanged, compared to its average volume of 95,706. The business has a 50 day simple moving average of $9.23 and a two-hundred day simple moving average of $7.46. BrainsWay has a 52 week low of $4.30 and a 52 week high of $10.98. The stock has a market capitalization of $152.12 million, a PE ratio of 91.21 and a beta of 1.25.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC boosted its position in shares of BrainsWay by 583.2% during the 1st quarter. Acadian Asset Management LLC now owns 175,416 shares of the company's stock worth $923,000 after purchasing an additional 149,740 shares in the last quarter. Good Life Advisors LLC boosted its holdings in BrainsWay by 65.5% in the third quarter. Good Life Advisors LLC now owns 55,800 shares of the company's stock worth $516,000 after acquiring an additional 22,080 shares in the last quarter. Perritt Capital Management Inc acquired a new stake in BrainsWay in the second quarter valued at approximately $121,000. Virtu Financial LLC bought a new stake in shares of BrainsWay during the first quarter valued at approximately $60,000. Finally, Rhumbline Advisers raised its position in shares of BrainsWay by 10.3% during the second quarter. Rhumbline Advisers now owns 18,077 shares of the company's stock worth $110,000 after purchasing an additional 1,695 shares during the period. Institutional investors and hedge funds own 30.11% of the company's stock.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.